X

Indication

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia... read more

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. read more

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.

Limitations of Use

  • Aranesp® has not been shown to improve quality of life, fatigue, or patient well-being.
  • Aranesp® is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.
› Email› Print

Converting patients on dialysis from epoetin alfa to QW Aranesp®

Enter the previous epoetin alfa per-week dose to see the corresponding Aranesp® doses for adults and children highlighted in the table below.

units/week Enter

Previous epoetin alfa dose

QW Aranesp® starting dose

(units/week)

Adult (mcg/week)

Child (mcg/week)

<1,500

6.25

*

1,500 to 2,499

6.25

6.25

2,500 to 4,999

12.5

10

5,000 to 10,999

25

20

11,000 to 17,999

40

40

18,000 to 33,999

60

60

34,000 to 89,999

100

100

≥90,000

200

200

*For pediatric patients receiving a weekly epoetin alfa dose of < 1.500 units/week. The available data are insufficient to determine an Aranesp® conversion dose.

Aranesp® is administered less frequently than epoetin alfa

  • Administer Aranesp® once weekly in patients who were receiving epoetin alfa 2 to 3 times weekly.
  • Administer Aranesp® once every 2 weeks in patients who were receiving epoetin alfa once weekly.
  • Maintain the route of administration (intravenous or subcutaneous injection).
  • The dose conversion in the chart above does not accurately estimate the once-monthly dose of Aranesp®.

Use the FDA-approved ESA conversion table in the Aranesp® PI to convert patients on dialysis from epoetin alfa to Aranesp®1

  • Pediatric patients with CKD: Aranesp® safety and efficacy were similar between adults and pediatric patients with CKD when Aranesp® was used for initial treatment of anemia or patients were transitioned from treatment with epoetin alfa to Aranesp®.

There is no single DCR when converting from epoetin alfa to Aranesp®1

  • Depending on the dose of epoetin alfa at the time of substitution, the Aranesp®:epoetin alfa DCR may range from 200:1 to 900:1.

DCRs vary from patient to patient, based on previous weekly dose
of epoetin alfa.1

Important Safety Information

  • For lack or loss of hemoglobin response to Aranesp®, initiate a search for causative factors. If typical causes of lack or loss of hemoglobin response are excluded, evaluate for PRCA.
  • Cases of PRCA and of severe anemia, with or without other cytopenias that arise following the development of neutralizing antibodies to erythropoietin have been reported in patients treated with Aranesp®.
    • This has been reported predominantly in patients with CKD receiving ESAs by subcutaneous administration.
    • PRCA has also been reported in patients receiving ESAs for anemia related to hepatitis C treatment (an indication for which Aranesp® is not approved).
    • If severe anemia and low reticulocyte count develop during treatment with Aranesp®, withhold Aranesp® and evaluate patients for neutralizing antibodies to erythropoietin.
    • Permanently discontinue Aranesp® in patients who develop PRCA following treatment with Aranesp® or other erythropoietin protein drugs. Do not switch patients to other ESAs.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
CKD = chronic kidney disease; DCR = dose conversion ratio; ESA = erythropoiesis-stimulating agent; QW = once weekly.
Reference: 1. Aranesp® (darbepoetin alfa) prescribing information, Amgen.